Use of photobiomodulation with blue light in the treatment of ulcers of various etiology in spinal cord injured patients: a case series

Submitted: March 27, 2023
Accepted: June 9, 2023
Published: July 25, 2023
Abstract Views: 341
PDF: 73
PDF (Italiano): 121
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

The case study sought to validate the efficacy of Photobiomodulation with Blue Light as a therapy for promoting the healing of skin lesions resistant to conventional therapies in patients with spinal cord injuries. 25 patients were treated for a total of 32 skin lesions of various etiologies, primarily 2nd, 3rd, or 4th-degree pressure ulcers (ref. EPUAP/NPUAP classification), that had been present for more than 90 days and showed no clinical signs of evolution toward healing, despite having already received advanced medication treatment in the Spinal Unit for more than 4 weeks. For photobiomodulation therapy, a class IIa medical device (EmoLED) was employed, which uses LED sources that generate blue light in the 410-430nm region. Blue Light treatment restarted the healing process in 68.7% of the ulcers treated, with an average level of re-epithelialization of 72.8%. Blue Light, based on our prior experience, is a therapy that can assist shorten treatment and hospitalization times while also improving patients' quality of life; it can also be utilized for frail patients because it is well tolerated and readily deployed.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Anders JJ, Lanzafame RJ, Arany PR. Low-level light/laser therapy versus photobiomodulation therapy. Photomed Laser Surg 2015;33:183–4. DOI: https://doi.org/10.1089/pho.2015.9848
Enwemeka C. Therapeutic Light. Rehab Manag 2004;17:20-7. DOI: https://doi.org/10.1016/S0961-1290(04)00159-0
Williams RK, Raimondo J, Cahn D, et al. Whole-organ transdermal photobiomodulation (PBM) of COVID-19: A 50-patient case study. J Biophotonics 2022;15:e202100194. Erratum in: J Biophotonics 2022;e202190015. DOI: https://doi.org/10.1002/jbio.202190015
Rossi F, Magni G, Tatini F, et al. Photobiomodulation of human fibroblasts and keratinocytes with blue light: implications in wound healing. Biomedicines 2021;9:41. DOI: https://doi.org/10.3390/biomedicines9010041
Magni G, Banchelli M, Cherchi F, et al. Experimental study on blue light interaction with human keloid-derived fibroblasts. Biomedicines 2020;8:573. DOI: https://doi.org/10.3390/biomedicines8120573
RomagnaniS.T-cellsubsets (Th1versusTh2). Ann Allergy Asthma Immunol 2000;85:9-18;quiz 18,21.
Landén NX, Li D, Ståhle M. Transition from inflammation to proliferation: a critical step during wound healing. Cell Molec Life Sci 2016;73:3861-85. DOI: https://doi.org/10.1007/s00018-016-2268-0
Mistry RK, Brewer AC. Redox regulation of gasotransmission in the vascular system: A focus on angiogenesis. Free Radical Biol Med 2017;108:500-16. DOI: https://doi.org/10.1016/j.freeradbiomed.2017.04.025
Hong WX, Hu MS, Esquivel M, et al. The role of hypoxia-inducible factor in wound healing. Adv Wound Care 2014;3:390-9. DOI: https://doi.org/10.1089/wound.2013.0520
Fraccalvieri M, Amadeo G, Bortolotti P, et al. Effectiveness of blue light photobiomodulation therapy in the treatment of chronic wounds. Results of the Blue Light for Ulcer Reduction (B.L.U.R.) Study. Ital J Dermatol Venerol 2022;157:187-194. DOI: https://doi.org/10.23736/S2784-8671.21.07067-5

How to Cite

Pezzuto, C., Felisi, N., Crispini, N., & Rosso, I. (2023). Use of photobiomodulation with blue light in the treatment of ulcers of various etiology in spinal cord injured patients: a case series. Italian Journal of Wound Care, 7(2). https://doi.org/10.4081/ijwc.2023.97